Wyniki wyszukiwania - Biblioteka Nauki

1

INFLUENCE OF PHYSICAL REHABILITATION ON SOCIAL NETWORKS AND QUALITY OF LIFE AMONG PEOPLE WITH PARKINSON’S DISEASE

100%

Lizoń K. , Cholewa J. , Uher I.

|

nr 10

35-42

XX

Parkinson's Disease (PD) is the second most common neurodegenerative disease. Symptoms relate to the movement and cognitive sphere; they have a negative impact on the quality of life of people suffering from PD. Pharmacotherapy and rehabilitation slow the progression of the disease. The aim of the work was to determine the impact of physical rehabilitation on the level of social relations in the context of the quality of life of people with PD. 47 people with idiopathic PD were involved in the study, all were in the second stage of the disease according to the Hoehn & Yahr scale. The Courage Social Network Index (CSNI) was used to assess social relations. The scales: Quality of Life in Parkinson’s Disease 39 (PDQ-39), Medical Outcomes Study 36-item Short-Form Heath Survey (SF-36) and Parkinson’s Disease Quality of Life Questionnaire (PDQL) were applied in order to evaluate the quality of life of patients The subjects were divided into two groups: research and control. The research group took part in a rehabilitation program two times a week for 45 minutes for three months. The control group did not participate in any form of physical rehabilitation. The results of the research showed a significantly higher level of social bonds as well as quality of life of people with PD participating in physical rehabilitation. At the same time, a higher level of correlation between the level of social bonds and the level of quality of life was found in the research group. Therefore, the positive impact of physical rehabilitation on the level of social bonds and the quality of life of people with PD constituted the conclusion of the work.

2

Physiological upper limb's tremor research using computer tablet

88%

Lech T.

|

tom Vol. 3, nr 1

81--89

EN

The paper presents the research results of the computer tablet application in the diagnostics of physiological tremor of hands. The said research is a continuation of a wider research process aiming at the creation of a compact diagnostic system of nervous system diseases appearing in, inter alia, hand's tremor. The application of properly programmed computer tablet makes it possible to carry out the examination of the upper limb's tremor in a fast, easy and cheap way, assisting the neurologists in the diagnostic process, therefore the use of a very expensive medical equipment (EMG, accelerometer) can be minimized. Needless to say, the compact diagnostic system of hands' tremor and co-related tremors of the nervous system pathology must correctly diagnose the physiological tremor. In order to do it a comparative examination has been performed in healthy patients whose physiologic tremor has been intensified by adequate methods. The application of the Fourier transform and time/frequency relation enabled the analysis of signals and performance of the comparative analysis involving the data gathered in patients with clinically confirmed Parkinson's disease.

3

Aparat rejestrujący drżenie w chorobie Parkinsona z zastosowaniem akcelerometru MEMS

75%

Karaś K. , Tutaj J.

|

tom z. 7

87--92

PL

Głównym celem artykułu jest opis prototypu aparatu do rejestracji drżenia, którego najważniejszym elementem jest akcelerometr. W artykule zawarto kryteria wyboru czujnika do pomiaru tremoru oraz wyjaśniono zasadę działania termicznego akcelerometru MEMS, który jest zasadniczym elementem skonstruowanego przyrządu. W celu zaprezentowania działania urządzenia zamieszczono przebiegi czasowe sygnału pomiarowego pochodzące od dwóch pacjentów ze zdiagnozowaną chorobą Parkinsona.

EN

The main aim of this article is to describe a prototype device for measuring tremor in Parkinson Disease. Device is based on thermal accelerometer constructed in MEMS technology The article includes criteria for selecting a sensor for measuring tremor and explains the principle of operation of thermal MEMS accelerometer. Article included measuring signal waveforms derived from two patients diagnosed with Parkinson's disease.

4

Parametric analysis of pilot voice signals in Parkinson’s disease diagnostics

75%

Majda-Zdancewicz E. , Potulska-Chromik A. , Nojszewska M. , Kostera-Pruszczyk A.

|

tom Vol. 4, No. 1

21--28

EN

Parkinson's disease (PD) is a neurodegenerative disease of the central nervous system (CNS) characterized by the progressive loss of dopaminergic neurons in the substantia nigra. The article describes an analysis of pilot voice signal analysis in Parkinson's disease diagnostics. Frequency domain signal analysis was mainly used to assess the state of a patient's voice apparatus in order to support PD diagnostics. The recordings covered uttering the “a” sound at least twice with extended phonation. The research utilized real recordings acquired in the Department of Neurology at the Medical University of Warsaw, Poland. Spectral speech signal coefficients may be determined based on different defined frequency scales. The authors used four frequency scales: linear, Mel, Bark and ERB . Spectral descriptors have been defined for each scales which are widely used in machine and deep learning applications, and perceptual analysis. The usefulness of extracted features was assessed taking into account various methods. The discriminatory ability of individual coefficients was evaluated using the Fisher coefficient and LDA technique.. The results of numerical experiments have shown different efficiencies of the proposed descriptors using different frequencies scales.

PL

Choroba Parkinsona (PD) jest neurodegeneracyjną chorobą ośrodkowego układu nerwowego charakteryzującą się postępującą utratą neuronów dopaminergicznych w istocie czarnej. W artykule opisano analizę rejestracji pilotażowych sygnałów głosu w diagnostyce choroby Parkinsona. Rejestracji podlegało co najmniej dwukrotnie wypowiadanie głoski "a” o przedłużonej fonacji. Do badań wykorzystano nagrania zarejestrowane w Katedrze i Klinice Neurologii Warszawskiego Uniwersytetu Medycznego w Warszawie. Do oceny stanu aparatu głosu pacjenta celem wsparcia diagnostyki choroby Parkinsona wykorzystano w głównej mierze analizę sygnału w dziedzinie częstotliwości. Autorzy zastosowali cztery skale częstości: liniową, skalę typu Mel, skalę typu Bark oraz skalę typu ERB. Dla każdej z tych skali zdefiniowali deskryptory spektralne szeroko stosowane w aplikacjach uczenia maszynowego i głębokiego uczenia się oraz w analizie percepcyjnej. Ocena przydatności wyekstrahowanych cech została zrealizowana z uwzględnieniem różnych metod. Wykorzystano metodą oceny jakości cech przy użyciu współczynnika istotności Fischera oraz analizę LDA. Wyniki eksperymentów numerycznych wykazały różne wydajności proponowanych deskryptorów przy użyciu różnych skal częstości.

5

Subthalamic nucleus deep brain stimulation in Parkinson's disease

75%

Mandat T. , Koziara H. , Nauman P. , Tykocki T. , Bonicki W.

|

2011

|

tom Vol. 31, no. 3

47-55

EN

A group of 37 patients diagnosed with Parkinson's disease (PD) were treated with subthalamic deep brain stimulation (STN DBS). The mean age at implantation was 59 - 11 years and PD has been present from 6 to 17 years (mean 9). The STN was identified by direct and indirect methods: macro stimulation and microrecording in all cases. At a three month follow-up, the authors observed a mean reduction of 49% in UPDRS II score and a mean reduction of 65% in UPDRS III score. Mean reduction of 1-dopa consumption was 62%. The authors concluded that STN DBS safely reduces disabling symptoms of PD.

6

An influence of lesions of the catecholaminergic cerebellar innervation on the harmaline-induced tremor in rats

75%

Wardas J. , Kolasiewicz W. , Kuter K. , Berghauzen K. , Nowak P. , Mikolajun U. , Zapala M. , Ossowska K.

|

tom 73

|

nr 1

EN

Recent studies have suggested a crucial role of the cerebellum in different forms of tremor. Abnormal synchronous activation of the glutamatergic olivo-cerebellar pathway and Purkinje cells results in the essential tremor in humans and the harmaline-induced tremor in animals. Moreover, an increased neuronal activity of the cerebellum has been found to contribute to the tremor in Parkinson’s disease (PD). Since the cerebellum receives dopaminergic and noradrenergic pathways arising from regions affected in PD, the aim of the present study was to examine a contribution of the cerebellar catecholaminergic innervation to the harmaline-induced tremor in rats. Rats were bilaterally injected into the cerebellar vermis (lobules 8–10) with 6-hydroxydopamine (6-OHDA) (8 μg/0.5 μl) either alone or this treatment was preceded by desipramine (15 mg/kg i.p.). Harmaline was administered at a dose of 7.5 mg/kg i.p. on the 9th post-operative day. Tremor of forelimbs was measured as a number of episodes. After completion of behavioural experiments rats were killed by decapitation and the levels of monoamines and their metabolites were measured by HPLC in lobules 1–3, 4–7 and 8–10 of the cerebellum. 6-OHDA injected alone decreased the noradrenaline level by ca. 40–80% in the cerebellum and enhanced the harmaline-induced tremor. When 6-OHDA administration was preceded by desipramine, it decreased dopaminergic transmission in some regions of the cerebellum but induced its compensatory activation in others. Finally no influence of the latter treatment on the tremor induced by harmaline was observed. The present study indicates that the noradrenergic innervation of the cerebellum plays an inhibitory role in the harmaline-induced tremor. The study was supported by the grant of the Ministry of Science and Higher Education No N N401 570638, and partly by Statutory Funds of the Department of Neuro-Psychopharmacology, Institute of Pharmacology, Polish Academy of Sciences, Cracow, Poland.

7

Ropinirol : generyczny lek przeciw chorobie Parkinsona

75%

Chmielowiec U.

|

tom T. 85, nr 5

347-348

PL

W Instytucie Farmaceutycznym opracowano wieloetapową syntezę otrzymywania chlorowodorku 4-[2-(dipropyloamino)-etylo]1,3-dihydro2H-indol-2-onu (chlorowodorek ropinirolu). Z dziesięciu etapów syntezy redukcja wyjściowego kwasu 2-metylo-3-nitrobenzoesowego do odpowiedniego alkoholu, reakcja przedłużenia łańcucha i redukcji z jednoczesną cyklizacją odgrywają decydującą rolę w procesie wytwarzania końcowego produktu.

EN

A 10-step synthesis was developed to prep. 99.8% pure 4[2-(dipropylamino)-ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride. Redn. of the starting 2-methyl-3-nitrobenzoic acid to a corresponding alcohol, the reaction of chain extension, and reductive cyclization to the indolone ring are the crucial steps.

8

Diagnosing Parkinson’s disease using the classification of speech signals

75%

Froelich W. , Wróbel K. , Porwik P.

Journal of Medical Informatics & Technologies

|

2014

|

tom Vol. 23

187--193

EN

This paper addressees the problem of an early diagnosis of Parkinson’s disease by the classification of characteristic features of person’s voice. A new, two-step classification approach is proposed. In the first step, the voice samples are classified using standard state-of-the-art classifiers. In the second step, the classified samples are assigned to patients and the final classification process based on majority criterion is performed. The advantage of using our new approach is the resulting, reliable patientoriented medical diagnose. The proposed two-step method of classification allows also to deal with the variable number of voice samples gathered for every patient. Preliminary experiments revealed quite satisfactory classification accuracy obtained during the performed leave-one-out cross validation.

9

Wykorzystanie nadgarstkowego rejestratora drżeń kończyn do monitorowania pacjentów z chorobami układu pozapiramidowego

75%

Kornacki W. , Pikiel M. , Dobrowiecka B. , Pakszys W.

|

2001

|

tom nr 146

145-151

10

Evaluation of chosen gait parameters in patients with the Parkinson's disease

75%

Sobolak M. , Minta P.

Physiotherapy

|

2009

|

tom 17

|

nr 1

45-52

PL

Celem pracy była ocena niektórych parametrów chodu osób z chorobą Parkinsona przy przechodzeniu odcinków prostych określonej trasy i slalomu. Badaniem objęto dwie grupy: grupę badawczą złożongą z 17 chorych na chorobę Parkinsona (średnia wieku 71 lat) i 17-osobową grupę kontrolną reprezentowaną przez osoby zdrowe (średnia wieku 70 lat). Badanie polegało na przejściu trasy, uwzględniającej odcinki proste i slalomu, wytyczonej wg pomysłu autorów pracy. Osoby z chorobą Parkinsona osiągały gorsze parametry chodu w stosunku do osób zdrowych w analogicznym przedziale wiekowym, zwłaszcza na odcinkach slalomu.

EN

The aim of the paper was to evaluate chosen gait parameters in patients with the Parkinson's disease while walking on straight sections and slalom of a chosen route. The research covered two groups: the examination group numbering 17 patients with the Parkinson's disease (average age 71 years) and the control group including 17 healthy people (average age 70 years). The examination was based on covering a route consisting of straight sections and slaloms, designed according to the idea of the authors. Patients with the Parkinson's disease achieved worse results in comparison with healthy people of similar age, especially on the slalom distances.

11

Brain energy metabolism in neurodegeneration of dopaminergic neurons in animal model of early Parkinson's disease: role of astrocytes

63%

Kuter K. , Olech L. , Glowacka U. , Paleczna M. , Kosmowska B. , Jurga A.

|

nr Suppl.1

EN

Glial pathology and energy metabolism changes in the brain precede symptoms of Parkinson’s disease (PD) and multiple other neurodegenerative diseases. Astrocytes govern and regulate a large part of the energy metabolism in the brain. Prolonged impairment of astrocytic functions could increase the vulnerability of dopaminergic neurons in the substantia nigra (SN). In this model, 40‑50% of dopaminergic neurons were selectively killed, causing transient locomotor disability compensated with time. We also induced death of astrocytes in the SN, simultaneously activating microglia but sparing the dopaminergic neurons. The astrocytes replenished after toxin withdrawal. We studied multiple markers of energy metabolism and mitochondrial oxidative phosphorylation (OxPhos) complex and supercomplex functioning during the early stages of neurodegeneration and compensation in the SN and striatum (STR). Death of astrocytes diminished the capability of the dopaminergic system to compensate for the degeneration of neurons. It caused a local energy deprivation, a shift in the usage of energy substrates, via increased glycogenolysis and glycolysis markers, ketone bodies availability, and fatty acid transport in remaining glial cells. Increased neuronal expression of CPT1c and astrocytic expression of CPT1a suggest adaptation in fatty acid use. On the other hand, lesion of dopaminergic neurons influenced OxPhos system and enhanced its functioning. Microglia activation also plays an important role in the processes of degeneration, compensation, and energy metabolism regulation. Modulation of its activation phenotypes might be beneficial towards the indicated processes. Astrocyte and microglia energetic influence is one of the factors in the neuronal compensatory mechanisms of dopaminergic system and might have a leading role in presymptomatic PD stages.

12

Role of the unfolded protein response in the pathogenesis of Parkinson’s disease

63%

Varma D. , Sen D.

|

nr 1

EN

Parkinson's disease is the second most common neurodegenerative disease which affects almost 1% of the population above the age of 60. It is is characterized by loss of dopaminergic neurons in the striatum and substantia nigra, coupled with the formation of intracellular Lewy bodies in degenerating neurons. Recent evidence suggests endoplasmic reticulum stress as a common and prominent occurrence in the progression of Parkinson's disease pathogenesis in the affected human brain. One of the cellular defense mechanism to combat endoplasmic reticulum stress due to excessive protein accumulation is through activation of the unfolded protein response pathway. In this review we focus on the impact and role of this unfolded protein response as a causative factor of Parkinson's disease leading to neurodegeneration.

13

Cepstral separation difference: A novel approach for speech impairment quantification in Parkinson's disease

63%

Khan T. , Westin J. , Dougherty M.

|

2014

|

tom Vol. 34, no. 1

25--34

EN

This paper introduces a novel approach, Cepstral Separation Difference (CSD), for quantification of speech impairment in Parkinson's disease (PD). CSD represents a ratio between the magnitudes of glottal (source) and supra-glottal (filter) log-spectrums acquired using the source-filter speech model. The CSD-based features were tested on a database consisting of 240 clinically rated running speech samples acquired from 60 PD patients and 20 healthy controls. The Guttmann (μ2) monotonic correlations between the CSD features and the speech symptom severity ratings were strong (up to 0.78). This correlation increased with the increasing textual difficulty in different speech tests. CSD was compared with some non-CSD speech features (harmonic ratio, harmonic-to-noise ratio and Mel-frequency cepstral coefficients) for speech symptom characterization in terms of consistency and reproducibility. The high intra-class correlation coefficient (>0.9) and analysis of variance indicates that CSD features can be used reliably to distinguish between severity levels of speech impairment. Results motivate the use of CSD in monitoring speech symptoms in PD.

14

mGluR5 NAMs as a potential treatments for L-DOPA-induced dyskinesia, Fragile X and gastroesophageal reflux

63%

Danysz W. , Dekundy A. , Gravius A. , Hechenberger M. , Klein K. U. , Parson C. G.

|

tom 73

|

nr 1

EN

Subtype 5 metabotropic glutamate receptors (mGluR5) have been implicated in the control of movement, mood, cognition, and nociception. Correspondingly, different mGluR5 antagonists have been shown to alleviate L-DOPA-induced dyskinesia (LID), anxiety, and pain in experimental animals. A novel proprietary mGluR5 antagonist 6,6-dimethyl-2-phenylethynyl-7,8-dihydro-6H-quinolin-5-one (MRZ-8676) having ~20 nM affinity to mGluR5, was tested in the rat models of LID, persistent pain, and anxiety. Effects of MRZ-8676 on motor performance and on learning were investigated. Presence of MRZ-8676 at target receptor in the brain was ascertained by measuring its extracellular concentrations and mGluR5 occupancy in vivo. MRZ-8676 had 20–25% bioavailability after oral treatment reaching Tmax at 2.9 h while T1/2 was 11.2 h. At 25 mg/kg p.o. Cmax was 348 ng/ml and AUC 2045 ng*h/ ml). In in vivo microdialysis experiments, pharmacologically effective p.o. doses of MRZ-8676 were found to achieve free brain concentrations sufficient to completely block mGluR5, i.e. above 100 nM. This finding was further confirmed by the results of the in vivo mGluR5 receptor occupancy study showing ED50 of ca. 5 mg/kg after i.p. administration. MRZ-8676 strongly and dose-dependently reduced abnormal involuntary movements in the 6-hydroxydopamine (6-OHDA) rat model of LID starting at 25 mg/kg. No tolerance of the antidyskinetic effects was observed upon subchronic (6-day) treatment with 75 mg/kg p.o. MRZ-8676 produced moderate anxiolytic effect in two rodent anxiety models, the contextual fear conditioning (at 25 mg/kg) and the elevated plus maze (25 mg/kg). At the same dose, MRZ-8676 also attenuated reaction to pain in the first phase of formalin test, the rat model of persistent pain induction. MRZ-8676 did not produce any detrimental effects on motor performance of rats as investigated rotarod test up to 150 mg/kg p.o. In the open field short lasting increase in locomotor activity was observed (25–150 mg/kg). However, MRZ-8676 dose dependently impaired learning in aversive learning paradigm of the contextual fear conditioning test reaching significance at 75 mg/kg which is above minima effective dose in tests for dyskinesia, pain or anxiety. Summing up, MRZ-8676 has clear-cut antidyskinetic properties with a sufficient therapeutic window. Moreover, it has anxiolytic and analgesic properties. Receptor occupancy and microdialysis studies indicate that the behavioural effects of MRZ-8676 are associated with blockade of mGluR5 in the brain. Moreover, preclinical rational and status of clinical trials with mGluR5 NAMs in Parkinson´s disease, Fragile X and gastroesophageal reflux will be presented.

15

Parkinson disease examination using walk disturbances characteristics

63%

Zbrojkiewicz J. S. , Piecha J.

|

tom Vol. 3

MI135--142

EN

This study is based on clinical observations of patient motor-disturbances, measured by PSW (Parotec System for Windows) pedobarographic recorder [1]. The gait regular asymmetry in a data spectrum has been noticed as an independent factor from disease duration and severity. In majority of analysed cases a gravity centre of the body moves towards a left limb, into a heel region. A trajectory of foot gravity centre elongation, its irregularity, a floor-contact time and impulse values increase is also visible. Predominantly on more affected limb. These diagnosis factors allow concluding that the PSW recorder could successfully be used for recognition and quantification of the motor disturbances, illustrating the Parkinson disease progress.

16

The influence of repetitive transcranial magnetic stimulation on sleep in parkinson's disease

63%

Antczak J. , Rakowicz M. , Banach M. , Derejko M. , Sienkiewicz J. , Zalewska U. , Więcławska M. , Jernajczyk W.

|

2011

|

tom Vol. 31, no. 3

35-46

EN

Sleep disturbance is common in Parkinson's disease (PD). In this study we investigated the effect of a novel therapeutic tool, repetitive transcranial magnetic stimulation (rTMS) on sleep quality in PD patients. The study group consisted of 11 PD patients who underwent ten daily rTMS sessions at 15 Hz. Their sleep patterns were monitored with polysomnography. After the stimulation, non-REM stage-1 sleep and the number of nocturnal arousals decreased, thus improving sleep quality. These changes were probably related to the improvement of motor symptoms observed in UPDRS and in the 9 Hole peg test.

17

Nowa metoda otrzymywania monohydratu dichlorowodorku pramipeksolu

63%

Balicki R. , Ciesielska A.

|

tom T. 85, nr 5

344-346

PL

Monohydrat dichlorowodorku pramipeksolu jest lekiem stosowanym w chorobie Parkinsona. Nowa, oryginalna metoda jego otrzymywania, opracowana w Instytucie Farmaceutycznym, charakteryzuje się niskimi kosztami, prostotą technologii i brakiem zanieczyszczeń metalami w końcowym produkcie.

EN

(S)-(-)-2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole was alkylated with 1-propyl p-toluenesulfonate in dimethylformamide as solvent for 96 hrs. at room temp. The heterogeneous reaction system did not dissolve (only the nature of the ppt. changed) and ensured min. polyalkylates. The resulting pramipexol tosylate was collected by filtration, dried in vacuo at 35oC, and converted into the monohydrous or anhyd. dihydrochloride. The method is cheap.

18

Benserazyd : lek wspomagający w terapii choroby Parkinsona : synteza związku o wysokiej czystości

63%

Zegrocka-Stendel O.

|

tom T. 85, nr 5

349-350

PL

Opisano metodę otrzymywania chlorowodorku benserazydu o wysokiej czystości, przekraczającej normy ustanowione przez farmakopeę.

EN

Hofman-La Roche’s (GB 947128 (1961) and GB 1250279 (1968)) route to benserazide can yield benserazide hydrochloride contg. <1% of alc.-insol. intermediates

19

Classification of speech intelligibility in Parkinson's disease

63%

Khan T. , Westin J. , Dougherty M.

|

2014

|

tom Vol. 34, no. 1

35--45

EN

A problem in the clinical assessment of running speech in Parkinson's disease (PD) is to track underlying deficits in a number of speech components including respiration, phonation, articulation and prosody, each of which disturbs the speech intelligibility. A set of 13 features, including the cepstral separation difference and Mel-frequency cepstral coefficients were computed to represent deficits in each individual speech component. These features were then used in training a support vector machine (SVM) using n-fold cross validation. The dataset used for method development and evaluation consisted of 240 running speech samples recorded from 60 PD patients and 20 healthy controls. These speech samples were clinically rated using the Unified Parkinson's Disease Rating Scale Motor Examination of Speech (UPDRS-S). The classification accuracy of SVM was 85% in 3 levels of UPDRS-S scale and 92% in 2 levels with the average area under the ROC (receiver operating characteristic) curves of around 91%. The strong classification ability of selected features and the SVM model supports suitability of this scheme to monitor speech symptoms in PD.

20

Family-based association analysis of the MAPT gene in Parkinson disease

63%

Wang K. S. , Mullersman J. E. , Liu X. F.

|

nr 4

EN

The MAPT gene has been shown to be associated with several neurodegenerative disorders, including forms of parkinsonism and Parkinson disease (PD), but the results reveal population differences. We investigated the association of 10 single-nucleotide polymorphisms (SNPs) in the region of MAPT on chromosome 17q21 with PD and age at onset, by using 443 discordant sib pairs in PD from a public dataset (Mayo-Perlegen LEAPS Collaboration). Association with PD was assessed by the FBAT using generalized estimating equations (FBAT-GEE), while the association with age at onset as a quantitative trait was evaluated using the FBAT-logrank statistic. Five SNPs were significantly associated with PD (P < 0.05) in an additive model, and 9 SNPs were associated with PD (P < 0.05) in dominant and recessive models. Interestingly, 8 PD-associated SNPs were also associated with age at onset of PD (P < 0.05) in dominant and recessive models. The SNP most significantly associated with PD and age at onset was rs 17649641 (P = 0.015 and 0.021, respectively). Two-SNP haplotypes inferred from rs 17563965 and rs 17649641 also showed association with PD (P = 0.018) and age at onset (P = 0.026). These results provide further support for the role of MAPT in development of PD.